Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295940 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3841136 in Healthy and Overweight Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT05295940: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT05295940 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 148 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05295940, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.
Primary Outcome
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Interventions
- DRUG Placebo
- DRUG LY3841136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2024-01-25 |
| Phase | Phase 1 |
What the finished NCT05295940 record still lists
NCT05295940 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05295940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05295940 about?
NCT05295940 is a clinical study titled "A Study of LY3841136 in Healthy and Overweight Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to...
What is the current status of trial NCT05295940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2022-03-30. Estimated completion is 2024-01-25.
What interventions are being tested in trial NCT05295940?
The interventions under investigation include: Placebo (DRUG), LY3841136 (DRUG).
Who is sponsoring clinical trial NCT05295940?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05295940's enrollment target sits among peer trials
148 382nd of 2000 higher than 1,614 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI